383 related articles for article (PubMed ID: 34445666)
21. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
22. Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands.
Liu QR; Pan CH; Hishimoto A; Li CY; Xi ZX; Llorente-Berzal A; Viveros MP; Ishiguro H; Arinami T; Onaivi ES; Uhl GR
Genes Brain Behav; 2009 Jul; 8(5):519-30. PubMed ID: 19496827
[TBL] [Abstract][Full Text] [Related]
23. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity.
Onaivi ES; Ishiguro H; Gu S; Liu QR
J Psychopharmacol; 2012 Jan; 26(1):92-103. PubMed ID: 21447538
[TBL] [Abstract][Full Text] [Related]
24. Allosteric modulation of the cannabinoid 2 receptor confers seizure resistance in mice.
Shapiro L; Gado F; Manera C; Escayg A
Neuropharmacology; 2021 May; 188():108448. PubMed ID: 33450277
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
26. CB2R induces a protective response against epileptic seizures through ERK and p38 signaling pathways.
Cao Q; Yang F; Wang H
Int J Neurosci; 2021 Aug; 131(8):735-744. PubMed ID: 32715907
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic potential of cannabinoid receptor ligands: current status.
Singh J; Budhiraja S
Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoid type 2 receptors mediate a cell type-specific self-inhibition in cortical neurons.
Stumpf A; Parthier D; Sammons RP; Stempel AV; Breustedt J; Rost BR; Schmitz D
Neuropharmacology; 2018 Sep; 139():217-225. PubMed ID: 30025920
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
30. CB2 receptor in the CNS: From immune and neuronal modulation to behavior.
Grabon W; Rheims S; Smith J; Bodennec J; Belmeguenai A; Bezin L
Neurosci Biobehav Rev; 2023 Jul; 150():105226. PubMed ID: 37164044
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases.
Hashiesh HM; Jha NK; Sharma C; Gupta PK; Jha SK; Patil CR; Goyal SN; Ojha SK
Eur J Pharmacol; 2021 Oct; 909():174398. PubMed ID: 34332924
[TBL] [Abstract][Full Text] [Related]
32. Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands.
Poso A; Huffman JW
Br J Pharmacol; 2008 Jan; 153(2):335-46. PubMed ID: 17982473
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Ashton JC; Wright JL; McPartland JM; Tyndall JD
Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
[TBL] [Abstract][Full Text] [Related]
34. N-Methyl-D-aspartate (NMDA) and cannabinoid CB
Rivas-Santisteban R; Lillo A; Lillo J; Rebassa JB; Contestí JS; Saura CA; Franco R; Navarro G
Alzheimers Res Ther; 2021 Nov; 13(1):184. PubMed ID: 34749800
[TBL] [Abstract][Full Text] [Related]
35. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Sep; 56(3):185-92. PubMed ID: 17656103
[TBL] [Abstract][Full Text] [Related]
36. Cannabis and Endocannabinoid Signaling in Epilepsy.
Katona I
Handb Exp Pharmacol; 2015; 231():285-316. PubMed ID: 26408165
[TBL] [Abstract][Full Text] [Related]
37. Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism.
Sierra S; Luquin N; Rico AJ; Gómez-Bautista V; Roda E; Dopeso-Reyes IG; Vázquez A; Martínez-Pinilla E; Labandeira-García JL; Franco R; Lanciego JL
Brain Struct Funct; 2015 Sep; 220(5):2721-38. PubMed ID: 24972960
[TBL] [Abstract][Full Text] [Related]
38. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
Shoemaker JL; Seely KA; Reed RL; Crow JP; Prather PL
J Neurochem; 2007 Apr; 101(1):87-98. PubMed ID: 17241118
[TBL] [Abstract][Full Text] [Related]
39. Regulation of cannabinoid CB
Salort G; Álvaro-Bartolomé M; García-Sevilla JA
Psychopharmacology (Berl); 2017 Mar; 234(6):925-941. PubMed ID: 28127623
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoid receptor 1/2 double-knockout mice develop epilepsy.
Rowley S; Sun X; Lima IV; Tavenier A; de Oliveira ACP; Dey SK; Danzer SC
Epilepsia; 2017 Dec; 58(12):e162-e166. PubMed ID: 29105060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
